Vadadustat, a HIF Prolyl Hydroxylase Inhibitor, Improves Immunomodulatory Properties of Human Mesenchymal Stromal Cells

• Published in: Cells (Basel, Switzerland) Vol. 9; no. 11; p. 2396
• Main Authors: Zielniok, Katarzyna, Burdzinska, Anna, Kaleta, Beata, Zagozdzon, Radoslaw, Paczek, Leszek
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.11.2020; MDPI
• Subjects: AKB-6548; Enzyme inhibitors; Hydroxylases; Immunity; immunomodulation; mesenchymal stem cells; Physiological aspects; preconditioning; priming; Stem cells; Vadadustat; Poland; immunomodulation; priming; mesenchymal stem cells; Vadadustat; AKB-6548; secretome; chemotaxis; preconditioning
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells9112396

The therapeutic potential of mesenchymal stromal cells (MSCs) is largely attributed to their immunomodulatory properties, which can be further improved by hypoxia priming. In this study, we investigated the immunomodulatory properties of MSCs preconditioned with hypoxia-mimetic Vadadustat (AKB-6548, Akebia). Gene expression analysis of immunomodulatory factors was performed by real-time polymerase chain reaction (real-time PCR) on RNA isolated from six human bone-marrow derived MSCs populations preconditioned for 6 h with 40 μM Vadadustat compared to control MSCs. The effect of Vadadustat preconditioning on MSCs secretome was determined using Proteome Profiler and Luminex, while their immunomodulatory activity was assessed by mixed lymphocyte reaction (MLR) and Culturex transwell migration assays. Real-time PCR revealed that Vadadustat downregulated genes related to immune system: , , , , , , and , and upregulated , and . Vadadustat caused a marked decrease in the secretion of IL6 (by 51%), HGF (by 47%), CCL7 (MCP3) (by 42%) and CXCL8 (by 40%). Vadadustat potentiated the inhibitory effect of MSCs on the proliferation of alloactivated human peripheral blood mononuclear cells (PBMCs), and reduced monocytes-enriched PBMCs chemotaxis towards the MSCs secretome. Preconditioning with Vadadustat may constitute a valuable approach to improve the therapeutic properties of MSCs.